Tenpoint Therapeutics Ltd., a global, clinical-stage biotechnology company focused on developing treatments to rejuvenate vision in the aging eye, has appointed Carol Kearney as Chief Commercial Officer (CCO). Kearney will spearhead Tenpoint’s commercial strategy, including preparation of the potential U.S. launch of BRIMOCHOL PF, an investigational, preservative-free, once-daily eye drop designed to address the loss of near vision. “The appointment of Carol as our first Chief Commercial O...